Uncertainty now dominates the COVID vaccine outlook after official recommendations were stripped for a variety of groups.

User Agreement; Privacy Policy; Ad Choices; Site Map © 2025 American City Business Journals. All rights reserved. Use of ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Novavax's full FDA approval for NUVAXOVID is a transformative milestone, unlocking a $175M Sanofi payment and validating ...

The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.

Shares of Novavax Inc. NVAX slid 6.23% to $6.92 Wednesday, on what proved to be an all-around grim trading session for the ...

Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Nuvaxovid™ for active immunization to ...

Novavax shares jumped more than 15% on Monday after the company secured a long-awaited U.S. regulatory approval for its COVID ...

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it ...

Italian tyre maker Pirelli is in a risky situation after its Chinese leading shareholder Sinochem rejected a proposal by the ...

The U.S. Food and Drug Administration approved Novavax's COVID-19 vaccine with age restrictions after a six-week delay.